Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 3/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | FADS1 | O60427 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | GCK | P35557 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2081805 | 0.81 | NOS2 (0.65) | NOS2RECQLFADS1CYP3A4ABL1 | |
| SCHEMBL10749967 | 0.78 | NOS2 (0.62) | NOS2RECQLFADS1ABL1ALDH1A1 | |
| SCHEMBL2079618 | 0.77 | NOS2 (0.60) | NOS2RECQLFADS1CYP3A4ABL1 | |
| SCHEMBL8990156 | 0.77 | NOS2 (0.60) | NOS2RECQLFADS1ALDH1A1 | |
| SCHEMBL7806549 | 0.76 | NOS2 (0.58) | NOS2RECQLFADS1CYP3A4ABL1 | |
| SCHEMBL9376771 | 0.76 | NOS2 (0.59) | NOS2RECQLFADS1CYP3A4ABL1 | |
| SCHEMBL10748798 | 0.76 | NOS2 (0.59) | NOS2RECQL | |
| SCHEMBL2450666 | 0.75 | ALDH1A1 (0.61) | NOS2RECQLFADS1CYP3A4ABL1 | |
| SCHEMBL20556394 | 0.75 | NOS2 (0.73) | NOS2RECQLFADS1CYP3A4ABL1 | |
| SCHEMBL10964252 | 0.74 | NOS2 (0.60) | NOS2RECQLFADS1ABL1GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098483-A1 | Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098483-A1 | Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098483-A1 | Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2009121033-A2 | SUBSTITUTED NITROGEN HETEROCYCLES AND SYNTHESIS AND USES THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090247766-A1 | Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247766-A1 | Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247766-A1 | Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098483-A1 | Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof | PAH, NAT1, NNT | NOS2 20/4885RECQL 1260/4885FADS1 2515/4885 |
| US-20090247766-A1 | Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof | PAH, NAT1, NNT | NOS2 20/4885RECQL 1260/4885FADS1 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.